Beijing — China’s Shenzhen Stock Exchange said on Thursday it is seeking further information from shopping mall operator Guangdong Highsun Group after Highsun announced it was backing the development of an African swine fever vaccine.

Highsun said on Tuesday that it would spend 900-million yuan ($130.09m), or 26% of its 2018 net assets, on supporting research into a natural compound the company claimed had been shown to prevent African swine fever, a disease deadly to pigs that is ravaging herds across Asia.

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now